STI
8
4
TEL
74
5
MHK
75
5
FFIV
58
3
AMG
77
5
C
74
3
CRM
39
4
ITW
42
3
MAS
78
7
DNB
44
2
MET
51
3
OXY
55
6
DOV
48
6
FAST
52
3
PVH
34
2
DE
45
2
EOG
52
3
JPM
56
3
KIM
51
4
WAT
40
3
STI
8
4
TEL
74
5
MHK
75
5
FFIV
58
3
AMG
77
5
C
74
3
CRM
39
4
ITW
42
3
MAS
78
7
DNB
44
2
MET
51
3
OXY
55
6
DOV
48
6
FAST
52
3
PVH
34
2
DE
45
2
EOG
52
3
JPM
56
3
KIM
51
4
WAT
40
3
Financhill
Back

Apellis Pharmaceuticals 10K Form

Buy
56

APLS
Apellis Pharmaceuticals

Last Price:
$23.91
Seasonality Move:
6.92%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive APLS News And Ratings

See the #1 stock for the next 7 days that we like better than APLS

APLS Financial Statistics

Sales & Book Value

Annual Sales: $781.4M
Cash Flow: $4.4M
Price / Cash Flow: 677.14
Annual Sales: $1.24
Price / Book: 19.31

Profitability

EPS (TTM): -1.82000
Net Income (TTM): $-228.2M
Gross Margin: $663.6M
Return on Equity: -108.6%
Return on Assets: -26.41%

Apellis Pharmaceuticals Earnings Forecast

Key Apellis Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 7 years for APLS is 84.93%.
  • The Selling, General & Administrative Expenses for APLS have been equal to 64.13% of Gross Profit Margin.
  • The Research & Development expenses have been 41.92% of Revenue.
  • The Net Earning history of APLS is -25.32% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 6 years.

Apellis Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: APLS
CUSIP: 03753U
Website: apellis.com

Debt

Debt-to-Equity Ratio: 2.9
Current Ratio: 3.77
Quick Ratio: 2.99

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 2602.19

APLS Technical Analysis vs Fundamental Analysis

Buy
56
Apellis Pharmaceuticals (APLS) is a Buy

Is Apellis Pharmaceuticals a Buy or a Sell?